{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T23:42:45Z","timestamp":1790293365386,"version":"4.1.0"},"reference-count":146,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2019,5,14]],"date-time":"2019-05-14T00:00:00Z","timestamp":1557792000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Serotonin has important roles in the development of the brain and other organs. Manipulations of synaptic serotonin by drugs such as serotonin reuptake inhibitors (SRI) or serotonin norepinephrine reuptake inhibitors (SNRI) might alter their development and function. Of interest, most studies on the outcome of prenatal exposure to SRI in human have not found significant embryonic or fetal damage, except for a possible, slight increase in cardiac malformations. In up to a third of newborns exposed to SRI, exposure may induce transient neonatal behavioral changes (poor neonatal adaptation) and increased rate of persistent pulmonary hypertension. Prenatal SRI may also cause slight motor delay and language impairment but these are transient. The data on the possible association of prenatal SRIs with autism spectrum disorder (ASD) are inconsistent, and seem to be related to pre-pregnancy treatment or to maternal depression. Prenatal SRIs also appear to affect the hypothalamic hypophyseal adrenal (HPA) axis inducing epigenetic changes, but the long-term consequences of these effects on humans are as yet unknown. SRIs are metabolized in the liver by several cytochrome P450 (CYP) enzymes. Faster metabolism of most SRIs in late pregnancy leads to lower maternal concentrations, and thus potentially to decreased efficacy which is more prominent in women that are rapid metabolizers. Studies suggest that the serotonin transporter SLC6A4 promoter is associated with adverse neonatal outcomes after SRI exposure. Since maternal depression may adversely affect the child\u2019s development, one has to consider the risk of SRI discontinuation on the fetus and the child. As with any drug treatment in pregnancy, the benefits to the mother should be considered versus the possible hazards to the developing embryo\/fetus.<\/jats:p>","DOI":"10.3390\/ijms20102370","type":"journal-article","created":{"date-parts":[[2019,5,14]],"date-time":"2019-05-14T10:42:33Z","timestamp":1557830553000},"page":"2370","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["SSRIs and SNRIs (SRI) in Pregnancy: Effects on the Course of Pregnancy and the Offspring: How Far Are We from Having All the Answers?"],"prefix":"10.3390","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7268-3512","authenticated-orcid":false,"given":"Asher","family":"Ornoy","sequence":"first","affiliation":[{"name":"Laboratory of Teratology, Department of Medical Neurobiology, Hebrew University Hadassah Medical School, Jerusalem 91120, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gideon","family":"Koren","sequence":"additional","affiliation":[{"name":"Maccabi Institute of Research and Innovation, Tel Aviv University, Tel Aviv, Israel and Ariel University, Ariel 40700, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2019,5,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1146\/annurev.med.60.042307.110802","article-title":"The expanded biology of serotonin","volume":"60","author":"Berger","year":"2009","journal-title":"Annu. Rev. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.neuroscience.2016.02.037","article-title":"Developmental changes in serotonin signaling: Implications for early brain function, behavior and adaptation","volume":"342","author":"Brummelte","year":"2017","journal-title":"Neuroscience"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1016\/j.jadohealth.2012.04.009","article-title":"Fetal serotonin signaling: Setting pathways for early childhood development and behavior","volume":"51","author":"Oberlander","year":"2012","journal-title":"J. Adolesc. Health."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.smrv.2010.11.003","article-title":"Serotonin control of sleep-wake behavior","volume":"15","author":"Monti","year":"2011","journal-title":"Sleep Med. Rev."},{"key":"ref_5","first-page":"1","article-title":"Selective serotonin reuptake inhibitors in human pregnancy: To treat or not to treat","volume":"2012","author":"Ornoy","year":"2012","journal-title":"Obstet. Gynecol. Int."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1001\/jama.2015.5605","article-title":"Antidepressant use late in pregnancy and risk of persistent pulmonary hypertension of the newborn","volume":"313","author":"Huybrechts","year":"2015","journal-title":"JAMA"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.siny.2013.11.007","article-title":"Selective serotonin reuptake inhibitors in human pregnancy: On the way to resolving the controversy","volume":"19","author":"Ornoy","year":"2014","journal-title":"Semin. Fetal Neonatal Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1002\/bdr2.1085","article-title":"New Insights into How Serotonin Selective Reuptake Inhibitors Shape the Developing Brain","volume":"109","author":"Gingrich","year":"2017","journal-title":"Birth Defects Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1002\/bdr2.1078","article-title":"Selective Serotonin Reuptake Inhibitors during pregnancy: Do we have now more definite answers related to prenatal exposure","volume":"109","author":"Ornoy","year":"2017","journal-title":"Birth Defects Res. Part C"},{"key":"ref_10","first-page":"1139","article-title":"SSRIs use in pregnant women; pharmacogenetics, drug-drug interactions and adverse effects","volume":"19","author":"Ornoy","year":"2018","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0143-4004(05)80465-5","article-title":"Partial purification and characterization of the human placental serotonin transporter","volume":"14","author":"Ramamoorthy","year":"1993","journal-title":"Placenta"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1055\/s-0028-1103296","article-title":"Placental transfer of SSRI and SNRI antidepressants and effects on the neonate","volume":"42","author":"Rampono","year":"2009","journal-title":"Pharmacopsychiatry"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1097\/01.ede.0000239581.76793.ae","article-title":"Maternal use of selective serotonin reuptake inhibitors and risk of congenital malformations","volume":"17","author":"Wogelius","year":"2006","journal-title":"Epidemiology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1056\/NEJMoa066584","article-title":"Use of selective serotonin-reuptake inhibitors in pregnancy and risk of birth defects","volume":"356","author":"Alwan","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/j.1365-2125.2008.03261.x","article-title":"Paroxetine and Fluoxetine in Pregnancy: A prospective, multi-center, controlled, observational study","volume":"66","author":"Shechtman","year":"2008","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1001\/jamapsychiatry.2016.1520","article-title":"Antipsychotic use in pregnancy and the risk for congenital malformations","volume":"73","author":"Huybrechts","year":"2016","journal-title":"JAMA Psychiatry"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2147\/CLEP.S9256","article-title":"Use of selective serotonin-reuptake inhibitors during early pregnancy and risk of congenital malformations: Updated analysis","volume":"2","author":"Kornum","year":"2010","journal-title":"Clin. Epidemiol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/bdrb.20144","article-title":"Major congenital malformations following prenatal exposure to serotonin reuptake inhibitors and benzodiazepines using population-Based health data","volume":"83","author":"Oberlander","year":"2008","journal-title":"Birth Defects Res. B Dev. Reprod Toxicol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"b3569","DOI":"10.1136\/bmj.b3569","article-title":"Selective serotonin reuptake inhibitors in pregnancy and congenital malformations: Population based cohort study","volume":"339","author":"Pedersen","year":"2009","journal-title":"BMJ"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Jordan, S., Morris, J.K., Davies, G.I., Tucker, D., Thayer, D.S., Luteijn, J.M., Morgan, M., Garne, E., Hansen, A.V., and Klungs\u00f8yr, K. (2016). Selective Serotonin Reuptake Inhibitor (SSRI) Antidepressants in Pregnancy and Congenital Anomalies: Analysis of Linked Databases in Wales, Norway and Funen, Denmark. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0165122"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1186\/1471-2393-14-333","article-title":"Increased risk of severe congenital heart defects in offspring exposed to selective serotonin-reuptake inhibitors in early pregnancy-an epidemiological study using validated EUROCAT data","volume":"14","author":"Knudsen","year":"2014","journal-title":"BMC Pregnancy Child Birth"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Daud, A.N., Bergman, J.E., Kerstjens-Frederikse, W.S., Groen, H., and Wilffert, B. (2016). The Risk of Congenital Heart Anomalies Following Prenatal Exposure to Serotonin Reuptake Inhibitors-Is Pharmacogenetics the Key?. Int. J. Mol. Sci., 17.","DOI":"10.3390\/ijms17081333"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1002\/bdra.20641","article-title":"First trimester use of paroxetine and congenital heart defects: A population-based case-control study","volume":"88","author":"Bakker","year":"2010","journal-title":"Birth Defects Res. A Clin. Mol. Teratol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/bdrb.20099","article-title":"First trimester exposure to paroxetine and risk of cardiac malformations in infants: The importance of dosage","volume":"80","author":"Ramos","year":"2007","journal-title":"Birth Defects Res. B Dev. Reprod. Toxicol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/bdra.20615","article-title":"Are selective serotonin reuptake inhibitors cardiac teratogens? Echocardiographic screening of newborns with persistent heart murmur","volume":"85","author":"Merlob","year":"2009","journal-title":"Birth Defects Res. A Clin. Mol. Teratol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1007\/s10654-015-0065-y","article-title":"Selective serotonin reuptake inhibitor antidepressant use in first trimester pregnancy and risk of specific congenital anomalies: A European register-based study","volume":"30","author":"Wemakor","year":"2015","journal-title":"Eur. J. Epidemiol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1007\/s00228-011-1021-8","article-title":"Antidepressant use during pregnancy: Comparison of data obtained from a prescription register and from antenatal care records","volume":"67","author":"Nilsson","year":"2011","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e001148","DOI":"10.1136\/bmjopen-2012-001148","article-title":"Exposure to selective serotonin reuptake inhibitors and the risk of congenital malformations: A nationwide cohort study","volume":"2","author":"Andersen","year":"2012","journal-title":"BMJ Open"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/acps.12042","article-title":"Antidepressant use in pregnancy: A critical review focused on risks and controversies","volume":"127","author":"Byatt","year":"2013","journal-title":"Acta Psychiatr. Scand."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1056\/NEJMoa067407","article-title":"First-trimester use of selective serotonin-reuptake inhibitors and risk of birth defects","volume":"356","author":"Louik","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1001\/jama.279.8.609","article-title":"Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors: A prospective controlled multicenter study","volume":"279","author":"Kulin","year":"1998","journal-title":"JAMA"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1097\/01.AOG.0000187302.61812.53","article-title":"Risks associated with selective serotonin reuptake inhibitors in pregnancy","volume":"106","author":"Malm","year":"2005","journal-title":"Obstet. Gynecol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1067\/mob.2003.172","article-title":"Birth outcomes after prenatal exposure to antidepressant medication","volume":"188","author":"Hendrick","year":"2003","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"23","DOI":"10.4065\/84.1.23","article-title":"Congenital heart disease associated with selective serotonin reuptake inhibitor use during pregnancy","volume":"84","author":"Wichman","year":"2009","journal-title":"Mayo Clin. Proc."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.clinthera.2007.05.003","article-title":"Paroxetine and congenital malformations: Meta-analysis and consideration of potential confounding factors","volume":"29","author":"Einarson","year":"2007","journal-title":"Clin. Ther."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1002\/bdra.20627","article-title":"First trimester paroxetine use and the prevalence of congenital, specifically cardiac, defects: A meta-analysis of epidemiological studies","volume":"88","author":"Wurst","year":"2010","journal-title":"Birth Defects Res. A Clin. Mol. Teratol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/bdra.20655","article-title":"Paroxetine exposure and during pregnancy and cardiac malformations","volume":"88","author":"Scialli","year":"2010","journal-title":"Birth Defects Res. A Clin. Mol. Teratol."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Gao, S.Y., Wu, Q.J., Sun, C., Zhang, T.N., Shen, Z.Q., Liu, C.X., Gong, T.T., Xu, X., Ji, C., and Huang, D.H. (2018). Selective serotonin reuptake inhibitor use during early pregnancy and congenital malformations: A systematic review and meta-analysis of cohort studies of more than 9 million births. BMC Med., 16.","DOI":"10.1186\/s12916-018-1193-5"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/S1701-2163(16)32918-8","article-title":"Does paroxetine cause cardiac malformations?","volume":"30","author":"Einarson","year":"2008","journal-title":"J. Obstet. Gynaecol. Can."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1017\/S0033291799001270","article-title":"Safety of fluoxetine during the first trimester of pregnancy; a meta-analytical review of epidemiological studies","volume":"30","author":"Addis","year":"2000","journal-title":"Psychol. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1002\/pds.1084","article-title":"Newer antidepressants and rates of major malformations; a meta-analysis of prospective comparative studies","volume":"14","author":"Einarson","year":"2005","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.reprotox.2006.03.019","article-title":"Pregnancy outcomes following exposure to serotonin reuptake inhibitors: A meta-analysis of clinical trials","volume":"22","author":"Rahimi","year":"2006","journal-title":"Reprod. Toxicol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1111\/bcp.12849","article-title":"The risk of major cardiac malformations associated with paroxetine use during the first trimester of pregnancy: A systematic review and meta-analysis","volume":"81","author":"Iessa","year":"2016","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e001681","DOI":"10.1161\/JAHA.114.001681","article-title":"Selective Serotonin Reuptake Inhibitors (SSRIs) and the Risk of Congenital Heart Defects: A Meta-Analysis of Prospective Cohort Studies","volume":"4","author":"Wang","year":"2015","journal-title":"J. Am. Heart Assoc."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/tera.1420500202","article-title":"\u201cProof\u201d of human teratogenicity","volume":"50","author":"Shepard","year":"1994","journal-title":"Teratology"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1542\/peds.113.S3.957","article-title":"Environmental causes of human congenital malformations: The pediatrician\u2019s role in dealing with these complex clinical problems caused by a multiplicity of environmental and genetic factors","volume":"113","author":"Brent","year":"2004","journal-title":"Pediatrics"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Ban, L., Tata, L.J., West, J., Fiaschi, L., and Gibson, J.E. (2012). Live and Non-Live Pregnancy Outcomes among Women with Depression and Anxiety: A Population-Based Study. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0043462"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/S1701-2163(16)34177-9","article-title":"Rates of spontaneous and therapeutic abortions following use of antidepressants in pregnancy: Results from a large prospective database","volume":"31","author":"Einarson","year":"2009","journal-title":"J. Obstet. Gynaecol. Can."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1503\/cmaj.091208","article-title":"Use of antidepressants during pregnancy and the risk of spontaneous abortion","volume":"182","author":"Broy","year":"2010","journal-title":"Can. Med. Assoc. J."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/ppe.12160","article-title":"Maternal use of selective serotonin reuptake inhibitors and risk of miscarriage\u2014Assessing potential biases","volume":"29","author":"Johansen","year":"2015","journal-title":"Paediatr. Perinat. Epidemiol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1097\/AOG.0000000000000447","article-title":"Exposure to selective serotonin reuptake inhibitors in early pregnancy and the risk of miscarriage","volume":"124","author":"Andersen","year":"2014","journal-title":"Obstet. Gynecol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.reprotox.2019.01.003","article-title":"Pregnancy outcomes following maternal venlafaxine use: A prospective observational comparative cohort study","volume":"84","author":"Richardson","year":"2019","journal-title":"Reprod. Toxicol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.ajog.2006.02.019","article-title":"Selective serotonin reuptake inhibitors and adverse pregnancy outcome","volume":"194","author":"Wen","year":"2006","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1001\/archpediatrics.2009.164","article-title":"Selective serotonin reuptake inhibitor exposure and pregnancy outcomes","volume":"163","author":"Lund","year":"2009","journal-title":"Arch. Pediatr. Adolesc. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1177\/070674371005501000","article-title":"Association between antidepressant use during pregnancy and infants born small for gestational age","volume":"55","author":"Ramos","year":"2010","journal-title":"Can. J. Psychiatry"},{"key":"ref_56","first-page":"e1","article-title":"Risks of preterm delivery and other adverse perinatal outcomes in relation to maternal use of psychotropic medications during pregnancy","volume":"579","author":"Qiu","year":"2009","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1097\/JCP.0b013e3181bf344c","article-title":"antidepressant use during pregnancy and the risk of preterm delivery and fetal growth restriction","volume":"29","author":"Toh","year":"2009","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1176\/appi.ajp.2015.14121575","article-title":"Pregnancy Complications Following Prenatal Exposure to SSRIs or Maternal Psychiatric Disorders: Results from Population-Based National Register Data","volume":"172","author":"Malm","year":"2015","journal-title":"Am. J. Psychiatry"},{"key":"ref_59","first-page":"706","article-title":"Maternal use of selective serotonin reuptake inhibitors, fetal growth, and risk of adverse birth outcomes","volume":"69","author":"Jaddoe","year":"2012","journal-title":"Arch. Gen. Psychiatry"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.jad.2018.08.061","article-title":"A meta-analysis of selective serotonin reuptake inhibitors (SSRIs) use during prenatal depression and risk of low birth weight and small for gestational age","volume":"241","author":"Zhao","year":"2018","journal-title":"J. Affect. Disord."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1177\/070674370404901103","article-title":"Perinatal risks of untreated depression during pregnancy","volume":"49","author":"Bonari","year":"2004","journal-title":"Can. J. Psychiatry"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1080\/14767050701209560","article-title":"Depression and anxiety during pregnancy; a risk factor for obstetric fetal and neonatal outcome? A critical review of the literature","volume":"20","author":"Alder","year":"2007","journal-title":"J. Matern. Fetal Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s002280050357","article-title":"Withdrawal reactions with selective serotonin re-uptake inhibitors as reported to the WHO system","volume":"53","author":"Stahl","year":"1997","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"291","DOI":"10.4088\/JCP.v58n0702","article-title":"Discontinuation symptoms after treatment with serotonin reuptake inhibitors: A literature review","volume":"58","author":"Zajecka","year":"1997","journal-title":"J. Clin. Psychiatry"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1001\/archpedi.158.4.312","article-title":"Neonate characteristics after maternal use of antidepressants in late pregnancy","volume":"158","year":"2004","journal-title":"Arch. Pediatr. Adolesc. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/archpedi.160.2.173","article-title":"Neonatal abstinence syndrome after in utero exposure to selective serotonin reuptake inhibitors in term infants","volume":"160","author":"Merlob","year":"2006","journal-title":"Arch. Pediatr. Adolesc. Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"e20160181","DOI":"10.1542\/peds.2016-0181","article-title":"Neonatal Morbidity after Maternal Use of Antidepressant Drugs During Pregnancy","volume":"138","author":"Forsberg","year":"2016","journal-title":"Pediatrics"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1056\/NEJMoa052744","article-title":"Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn","volume":"354","author":"Chambers","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1002\/pds.1570","article-title":"Maternal use of selective serotonin re-uptake inhibitors and persistent pulmonary hypertension of the newborn","volume":"17","year":"2008","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1002\/pds.1710","article-title":"Antidepressant medication use and risk of persistent pulmonary hypertension of the newborn","volume":"18","author":"Andrade","year":"2009","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1055\/s-0030-1262507","article-title":"Persistent pulmonary hypertension of the newborn is associated with mode of delivery and not with maternal use of selective serotonin reuptake inhibitors","volume":"28","author":"Wilson","year":"2011","journal-title":"Am. J. Perinatol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1111\/bcp.13194","article-title":"SSRI and SNRI use during pregnancy and the risk of persistent pulmonary hypertension of the newborn","volume":"83","author":"Sheehy","year":"2017","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.ajog.2018.08.030","article-title":"Prenatal exposure to selective serotonin reuptake inhibitors and serotonin norepinephrine reuptake inhibitors and risk for persistent pulmonary hypertension of the newborn: A systematic review, meta-analysis, and network meta-analysis","volume":"220","author":"Masarwa","year":"2019","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/jp.2010.211","article-title":"Long-term outcome following selective serotonin reuptake inhibitor induced neonatal abstinence syndrome","volume":"9","author":"Klinger","year":"2011","journal-title":"J. Perinatol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0378-4274(02)00505-2","article-title":"The impact of intrauterine exposure versus postnatal environment in neurodevelopment toxicity: Long term neurobehavioral studies in children at risk for developmental disorders","volume":"140\/141","author":"Ornoy","year":"2003","journal-title":"Toxicol. Lett."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/0145-2134(96)00014-2","article-title":"The developmental outcome of children born to heroin dependent mothers, raised at home or adopted","volume":"20","author":"Ornoy","year":"1996","journal-title":"Child Abuse Neglect."},{"key":"ref_77","first-page":"668","article-title":"The developmental outcome of school age children born to heroin- dependent mothers: Importance of environmental factors","volume":"43","author":"Ornoy","year":"2001","journal-title":"Dev. Med. Child. Neurol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.reprotox.2017.05.003","article-title":"Neurobehavioral risks of SSRIs in pregnancy: Comparing human and animal data","volume":"72","author":"Ornoy","year":"2017","journal-title":"Reprod. Toxicol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1056\/NEJM199701233360404","article-title":"Neurodevelopment of children exposed in utero to antidepressants drugs","volume":"336","author":"Nulman","year":"1997","journal-title":"N. Eng. J. Med."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1176\/appi.ajp.159.11.1889","article-title":"Child development following exposure to tricyclic antidepressants or fluoxetine throughout fetal life: A prospective controlled study","volume":"159","author":"Nulman","year":"2002","journal-title":"Am. J. Psychiatry"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1176\/appi.ajp.2012.11111721","article-title":"Neurodevelopment of children following prenatal exposure to venlafaxine, selected serotonin reuptake inhibitors, or untreated maternal depression","volume":"169","author":"Nulman","year":"2012","journal-title":"Am. J. Psychiatry"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"e842","DOI":"10.4088\/JCP.14m09240","article-title":"Neurodevelopment of children prenatally exposed to selective serotonin reuptake inhibitor antidepressants: Toronto sibling study","volume":"76","author":"Nulman","year":"2015","journal-title":"J. Clin. Psychiatry"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1176\/ajp.2006.163.6.1026","article-title":"Internalizing behaviors in 4-year old children exposed in-utero to psychotropic medications","volume":"163","author":"Misri","year":"2006","journal-title":"Am. J. Psychiatry"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1001\/archpedi.161.1.22","article-title":"Externalizing and attentional behaviors in children of depressed mothers treated with a selective serotonin reuptake inhibitor antidepressant during pregnancy","volume":"161","author":"Oberlander","year":"2007","journal-title":"Arch. Pediatr. Adolesc. Med."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1067\/mpd.2003.139","article-title":"Follow up of children of depressed mothers exposed or not exposed to antidepressants drugs during pregnancy","volume":"142","author":"Casper","year":"2003","journal-title":"J. Pediatr."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"e600","DOI":"10.1542\/peds.2008-3655","article-title":"Fetal exposure to antidepressants and normal milestone development at 6 and 19 months of age","volume":"125","author":"Pedersen","year":"2010","journal-title":"Pediatrics"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.earlhumdev.2012.12.012","article-title":"Infant developmental outcomes following prenatal exposure to antidepressants, and maternal depressed mood and positive affect","volume":"89","author":"Hanley","year":"2013","journal-title":"Early Hum. Dev."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.4088\/JCP.13m08902","article-title":"Impact of prenatal exposure to serotonin reuptake inhibitors or maternal major depressive disorder on infant developmental outcomes","volume":"75","author":"Santucci","year":"2014","journal-title":"J. Clin. Psychiatry"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"e176","DOI":"10.4088\/JCP.14m09348","article-title":"Preschool outcomes following prenatal serotonin reuptake inhibitor exposure: Differences in language and behavior, but not cognitive function","volume":"77","author":"Johnson","year":"2016","journal-title":"J. Clin. Psychiatry"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1001\/jamapsychiatry.2016.2594","article-title":"Association of Selective Serotonin Reuptake Inhibitor Exposure During Pregnancy With Speech, Scholastic, and Motor Disorders in Offspring","volume":"73","author":"Brown","year":"2016","journal-title":"JAMA Psychiatry"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.jaac.2016.02.013","article-title":"Gestational exposure to selective serotonin reuptake inhibitors and offspring psychiatric disorders: A National Register-Based Study","volume":"55","author":"Malm","year":"2016","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/acps.12867","article-title":"Exposure to selective serotonin reuptake inhibitors in utero and early elementary school outcomes","volume":"137","author":"Kragholm","year":"2018","journal-title":"Acta Psychiatr. Scand."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/aur.1288","article-title":"Serotonin hypothesis of autism: Implications for selective serotonin reuptake inhibitor use during pregnancy","volume":"6","author":"Harrington","year":"2013","journal-title":"Autism Res."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1001\/archgenpsychiatry.2011.73","article-title":"Antidepressant use during pregnancy and childhood autism spectrum disorders","volume":"68","author":"Croen","year":"2011","journal-title":"Arch. Gen. Psychiatry"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"e1241","DOI":"10.1542\/peds.2013-3406","article-title":"Prenatal SSRI use and offspring with autism spectrum disorder or developmental delay","volume":"133","author":"Harrington","year":"2014","journal-title":"Pediatrics"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1001\/jamapediatrics.2015.3356","article-title":"Antidepressant Use During Pregnancy and the Risk of Autism Spectrum Disorder in Children","volume":"170","author":"Boukhris","year":"2016","journal-title":"JAMA Pediatr."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/mp.2014.90","article-title":"Prenatal antidepressant exposure is associated with risk for attention-deficit hyperactivity disorder but not autism spectrum disorder in a large health system","volume":"20","author":"Clements","year":"2015","journal-title":"Mol. Psychiatry"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"e708","DOI":"10.1038\/tp.2015.190","article-title":"Absence of evidence for increase in risk for autism or attention-deficit hyperactivity disorder following antidepressant exposure during pregnancy: A replication study","volume":"6","author":"Castro","year":"2016","journal-title":"Transl. Psychiatry"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"f2059","DOI":"10.1136\/bmj.f2059","article-title":"Parental depression, maternal antidepressant use during pregnancy and risk of autism spectrum disorder; population based case-control study","volume":"346","author":"Rai","year":"2013","journal-title":"BMJ"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.jaac.2013.05.010","article-title":"The association between autism spectrum disorder and psychotic experience in the Avon longitudinal study of parents and children (ALSPAC) birth cohort","volume":"52","author":"Sullivan","year":"2013","journal-title":"J. Am. Acad. Child Adolesce. Psychiatry"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1056\/NEJMoa1301449","article-title":"Use of selective serotonin reuptake inhibitors during pregnancy and risk of autism","volume":"369","author":"Hviid","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_102","first-page":"449","article-title":"Antidepressant exposure in pregnancy and risk of autism spectrum disorders","volume":"15","author":"Christensen","year":"2013","journal-title":"Clin. Epidemiol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1001\/jama.2017.3413","article-title":"Associations of Maternal Antidepressant Use During the First Trimester of Pregnancy With Preterm Birth, Small for Gestational Age, Autism Spectrum Disorder, and Attention-Deficit\/Hyperactivity Disorder in Offspring","volume":"317","author":"Sujan","year":"2017","journal-title":"JAMA"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"e016368","DOI":"10.1136\/bmjopen-2017-016368","article-title":"Risk of autism spectrum disorder in offspring following paternal use of selective serotonin reuptake inhibitors before conception: A population-based cohort study","volume":"7","author":"Yang","year":"2017","journal-title":"BMJ Open"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.neubiorev.2014.11.020","article-title":"Exposure to selective serotonin reuptake inhibitors during pregnancy and risk of autism spectrum disorder in children: A systematic review and meta-analysis of observational studies","volume":"49","author":"Man","year":"2015","journal-title":"Neurosci. Biobehav. Rev."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.eurpsy.2017.06.001","article-title":"Maternal SSRI exposure increases the risk of autistic offspring: A meta-analysis and systematic review","volume":"45","author":"Andalib","year":"2017","journal-title":"Eur. Psychiatry"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.jad.2015.04.048","article-title":"Prenatal antidepressant exposure and the risk of autism spectrum disorders in children. Are we looking at the fall of Gods?","volume":"182","author":"Gentile","year":"2015","journal-title":"J. Affect. Disord."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.reprotox.2016.09.013","article-title":"Prenatal selective serotonin reuptake inhibitor use and the risk of autism spectrum disorder in children: A systematic review and meta-analysis","volume":"66","author":"Kaplan","year":"2016","journal-title":"Reprod. Toxicol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1001\/jamapediatrics.2017.0124","article-title":"Risk for Autism Spectrum Disorders According to Period of Prenatal Antidepressant Exposure: A Systematic Review and Meta-analysis","volume":"171","author":"Mezzacappa","year":"2017","journal-title":"JAMA Pediatr."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.4088\/JCP.15r10194","article-title":"The association between antenatal exposure to selective serotonin reuptake inhibitors and autism: A Systematic Review and Meta-Analysis","volume":"78","author":"Brown","year":"2017","journal-title":"J. Clin. Psychiatry"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1039\/c8tx00102b","article-title":"Maternal SSRIs experience and risk of ASD in offspring: A review","volume":"7","author":"Fatima","year":"2018","journal-title":"Toxicol. Res."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.reprotox.2016.04.024","article-title":"Genetic and non-genetic animal models for Autism Spectrum Disorders (ASD)","volume":"64","author":"Ergaz","year":"2016","journal-title":"Reprod. Toxicol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/j.1749-6632.1996.tb15122.x","article-title":"Mechanisms and functions of serotonin neuronal systems: Opportunities for neuropeptide interactions","volume":"780","author":"Fuller","year":"1996","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/j.1749-6632.2009.04978.x","article-title":"Risk factors for development of depression and psychosis. Glucocorticoid receptors and pituitary implications for treatment with antidepressant and glucocorticoids","volume":"1179","author":"Pariante","year":"2009","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1590\/S1516-44462004000300009","article-title":"The hypothalamic pituitary adrenal axis, glucocorticoid receptor function and relevance to depression","volume":"26","author":"Juruena","year":"2004","journal-title":"Rev. Bras. Pisquitr."},{"key":"ref_116","first-page":"11","article-title":"Involvement and role of antidepressant drugs of the hypothalamic-pituitary-adrenal axis and glucocorticoid receptor function","volume":"30","author":"Nikisch","year":"2009","journal-title":"Neuro Endocrinol. Lett."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.psyneuen.2012.08.012","article-title":"Glucocorticoid excess and the developmental origins of disease: Two decades of testing the hypothesis-2012 Curt Richter Award Winner","volume":"38","author":"Reynolds","year":"2013","journal-title":"Psychoneuroendocrinology"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1530\/REP-13-0258","article-title":"Effects of maternal exposure to social stress during pregnancy: Consequences for mother and offspring","volume":"146","author":"Brunton","year":"2013","journal-title":"Reproduction"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1210\/en.2014-1643","article-title":"Gestational Diabetes alters offspring DNA methylation profiles in human and rat: Identification of key genes involved in endocrine system disorders, insulin signaling, diabetes signaling and IL-K signaling pathways","volume":"156","author":"Petropoulos","year":"2015","journal-title":"Endocrinology"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/bdrc.21090","article-title":"Effect of maternal diabetes on the embryo, fetus and children: Congenital anomalies, genetic and epigenetic changes and developmental outcomes","volume":"105","author":"Ornoy","year":"2015","journal-title":"Birth Defects Res. Part C"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/s41398-019-0412-y","article-title":"What do DNA methylation studies tell us about depression? A systematic review","volume":"9","author":"Li","year":"2019","journal-title":"Transl. Psychiatry"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/j.psyneuen.2012.11.020","article-title":"Escitalopram alters gene expression and HPA axis reactivity in rats following chronic overexpression of corticotropin-releasing factor from the central amygdala","volume":"38","author":"Flandreau","year":"2013","journal-title":"Psychoneuroendocrinology"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.yhbeh.2016.06.001","article-title":"Prenatal SSRI alters the hormonal and behavioral responses to stress in female mice: Possible role for glucocorticoid resistance","volume":"84","author":"Avitsur","year":"2016","journal-title":"Horm. Behav."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.ntt.2013.07.008","article-title":"Prenatal exposure to escitalopram and\/or stress in rats produces limited effects on endocrine, behavioral, or gene expression measures in adult male rats","volume":"39","author":"Bourke","year":"2013","journal-title":"Neurotoxicol. Teratol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.bbr.2016.05.062","article-title":"Fluoxetine normalizes the effects of prenatal maternal stress on depression- and anxiety-like behaviors in mouse dams and male offspring","volume":"311","author":"Salari","year":"2016","journal-title":"Behav. Brain Res."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.neuroscience.2012.06.034","article-title":"Developmental fluoxetine exposure differentially alters central and peripheral measures of the HPA system in adolescent male and female offspring","volume":"220","author":"Pawluski","year":"2012","journal-title":"Neuroscience"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1080\/15592294.2015.1026031","article-title":"Prenatal antidepressant exposure associated with CYP2E1 DNA methylation change in neonates","volume":"10","author":"Gurnot","year":"2015","journal-title":"Epigenetics"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.earlhumdev.2008.06.008","article-title":"Hypothalamic-pituitary-adrenal (HPA) axis function in 3-month old infants with prenatal selective serotonin reuptake inhibitor (SSRI) antidepressant exposure","volume":"84","author":"Oberlander","year":"2008","journal-title":"Early Hum. Dev."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.psyneuen.2011.11.011","article-title":"Prenatal SSRI exposure alters neonatal corticosteroid binding globulin, infant cortisol levels, and emerging HPA function","volume":"37","author":"Pawluski","year":"2012","journal-title":"Psychoneuroendocrinology"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1002\/(SICI)1520-6394(1998)7:1+<24::AID-DA7>3.0.CO;2-F","article-title":"New antidepressants and the cytochrome P450 system: Focus on venlafaxine, nefazodone, and mirtazapine","volume":"7","author":"Owen","year":"1998","journal-title":"Depress. Anxiety."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2174\/1389200023338017","article-title":"Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions: An update","volume":"3","author":"Hemeryck","year":"2002","journal-title":"Curr. Drug Metab."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"281","DOI":"10.2165\/11539240-000000000-00000","article-title":"Clinical pharmacokinetics and drug interactions","volume":"50","author":"Knadler","year":"2011","journal-title":"Clin. Pharmacokinet."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00003088-199700321-00003","article-title":"Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism","volume":"32","author":"Preskorn","year":"1997","journal-title":"Clin. Pharmacokinet."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"i5014","DOI":"10.1136\/bmj.i5014","article-title":"Risk of mortality with concomitant use of tamoxifen and selective serotonin reuptake inhibitors: Multi-database cohort study","volume":"354","author":"Donneyong","year":"2016","journal-title":"BMJ"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"e95","DOI":"10.4088\/JCP.13f08941","article-title":"Selective serotonin reuptake inhibitor drug interactions in patients receiving statins","volume":"75","author":"Andrade","year":"2014","journal-title":"J. Clin. Psychiatry"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1097\/JCP.0000000000000658","article-title":"Clinical Outcomes of Concomitant Use of Warfarin and Selective Serotonin Reuptake Inhibitors: A Multidatabase Observational Cohort Study","volume":"37","author":"Dong","year":"2017","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/cpt.147","article-title":"Clinical Pharmacogenetics Implementation Consortium (CPIC). Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors","volume":"98","author":"Hicks","year":"2015","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/jcpt.12188","article-title":"Concentrations of venlafaxine and its main metabolite O-desmethylvenlafaxine during pregnancy","volume":"39","author":"Bosman","year":"2014","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/S0009-9236(02)17634-X","article-title":"Pharmacokinetics of fluoxetine and norfluoxetine in pregnancy and lactation","volume":"73","author":"Heikkinen","year":"2003","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1124\/dmd.112.050161","article-title":"A physiologically based pharmacokinetic model to predict disposition of CYP2D6 and CYP1A2 metabolized drugs in pregnant women","volume":"41","author":"Ke","year":"2013","journal-title":"Drug Metab. Dispos."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"677","DOI":"10.2165\/11318050-000000000-00000","article-title":"Effect of cytochrome P450 2D6 genotype on maternal paroxetine plasma concentrations during pregnancy","volume":"48","author":"Ververs","year":"2009","journal-title":"Clin. Pharmacokinet."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"402","DOI":"10.3389\/fphar.2017.00402","article-title":"OTIS (MotherToBaby) Collaborative Research Committee. Association between CYP2D6 Genotypes and the Risk of Antidepressant Discontinuation, Dosage Modification and the Occurrence of Maternal Depression during Pregnancy","volume":"8","author":"Gaedigk","year":"2017","journal-title":"Front. Pharmacol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1021\/acschemneuro.5b00287","article-title":"Maternal Pharmacokinetics and Fetal Disposition of (\u00b1)-Citalopram during Mouse Pregnancy","volume":"7","author":"Velasquez","year":"2016","journal-title":"ACS Chem. Neurosci."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1097\/01.AOG.0000116689.75396.5f","article-title":"Prevalence of depression during pregnancy: Systematic review","volume":"103","author":"Bennett","year":"2004","journal-title":"Obstet. Gynecol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.4088\/JCP.v65n0911","article-title":"Breastfeeding during maternal antidepressant treatment with serotonin reuptake inhibitors: Infant exposure, clinical symptoms, and cytochrome p450 genotypes","volume":"65","author":"Berle","year":"2004","journal-title":"J. Clin. Psychiatry"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/sj.mp.4002007","article-title":"Infant serotonin transporter (SLC6A4) promoter genotype is associated with adverse neonatal outcomes after prenatal exposure to serotonin reuptake inhibitor medications","volume":"13","author":"Oberlander","year":"2008","journal-title":"Mol. Psychiatry"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/20\/10\/2370\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:51:37Z","timestamp":1760187097000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/20\/10\/2370"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,14]]},"references-count":146,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2019,5]]}},"alternative-id":["ijms20102370"],"URL":"https:\/\/doi.org\/10.3390\/ijms20102370","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,14]]}}}